GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity
Could these 2 stocks outperform most GLP-1-focused companies over the medium term?
Overview
The GLP-1 market is booming. It may be one of the fastest-growing areas in the pharmaceutical industry, as medicines in this category are showing the potential to treat many conditions beyond diabetes and weight management, including obstructive sleep apnea, osteoarthritis pain, metabolic dysfunction-associated steatohepatitis, and others. It's no wonder investors are looking to capitalize on this by backing companies developing promising GLP-1 drugs.
However, oncology remains the largest therapeutic area by sales, and important breakthroughs are underway in that market. Summit Therapeutics (NASDAQ:SMMT) and Revolution Medicines (NASDAQ:RVMD) are two biotechs that could make important contributions to oncology. But are these stocks worth investing in?
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.